| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2015-1062
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2015-008 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-14542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-4925
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M27-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-0205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate |
2015-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-107206049-B |
| titleOfInvention |
Methods of treating patients with type 1 hepatorenal syndrome |
| abstract |
The principles and embodiments of the present disclosure relate to methods of using terlipressin to treat patients with impaired renal function associated with liver disease. A patient identified as having HRS-1 is tested to determine whether the patient meets at least two of three criteria, wherein the three criteria include WBC <4 or >12 cells/μL; HR >90 bpm; HCO3 < Either 21mmol/L or PaCO2<32mmHg or >20 breaths/min. If the patient meets at least two of the criteria, he or she is administered terlipressin in an amount effective to produce at least a 1.0 mg/dL reduction in serum creatinine. |
| priorityDate |
2014-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |